Heart failure patients benefit from the addition of a β-blocker to the standard heart failure regimen.1 The question of which β-blocker yields the greatest effect is still the subject of current research. I would like to provide additional information on β-blockers that was mentioned in “Using Carvedilol to Treat Heart Failure” (April 2002:36–58). The author explained the use of carvedilol in heart failure; however, it is important to mention that there are only 3 β-blockers approved by the Food and Drug Administration (FDA) for use in heart failure: carvedilol (Coreg), metoprolol succinate (Toprol-XL), and bisoprolol (Zebeta).

Like the author suggests, not all β-blockers are the same. Nor is it clear that β-blockers of the same generation are the same. Like carvedilol, bucindolol, a third-generation β-blocker, also sought FDA approval for treatment in heart failure. The BEST trial studied the effects of bucindolol in 2708 New York Heart Association Class...

You do not currently have access to this content.